Severe Aortic Stenosis with Acute Myocardial Infarction and Refractory Heart Failure as the Main Clinical Manifestations: A Case Report

2019 ◽  
Vol 07 (02) ◽  
pp. 29-35
Author(s):  
媛 刘
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Case Report ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Clinical Manifestations ◽  
Refractory Heart Failure

scholarly journals Effect of subcutaneous oxycodone for end-stage heart failure due to severe aortic stenosis — A case report

2018 ◽  
Vol 17 (6) ◽  
pp. 187-189
Author(s):  
Shutaro Futami ◽  
Joji Ishikawa ◽  
Yukari Arima ◽  
Yukiko Mogami ◽  
Yoshiko Nemoto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Case Report ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Usefulness of Carperitide for the Treatment of Refractory Heart Failure due to Severe Acute Myocardial Infarction.

2001 ◽  
Vol 42 (3) ◽  
pp. 271-280 ◽  
Author(s):  
Migaku Kikuchi ◽  
Motoyuki Nakamura ◽  
Tomomi Suzuki ◽  
Madoka Sato ◽  
Toshitake Takino ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Refractory Heart Failure

scholarly journals Beta-blockers, and real clinical practice in Russia: the gap between the understanding of the doses of beta-blockers and subsequent prognosis in patients with cardiovascular disease

2017 ◽  
Vol 14 (3) ◽  
pp. 36-41
Author(s):  
I V Fomin ◽  
D S Polyakov
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Chronic Heart Failure ◽  
Beta Blockers ◽  
Previous History ◽  
Clinical Manifestations ◽  
Population Level ◽  
Cardiovascular Pathology ◽  
History Of

Presents an analysis of the reception beta-blockers in three epidemiological studies sections of the EPOKhA. Respondents in each slice (2002, 2007, 2017) were stratified into 5 subgroups: only suffering from hypertension - AH (subgroup AH), patients with stable angina pectoris, but in history and clinically has no evidence of acute myocardial infarction (AMI) and chronic heart failure (subgroup of coronary heart disease); after myocardial infarction, but do not have clinical manifestations of chronic heart failure (subgroup myocardial infarction); patients with acute myocardial infarction formed for any reason, but with no previous history of AMI (subgroup chronic heart failure), and patients with clinical manifestations of chronic heart failure after suffering AMI in anamnesis (subgroup myocardial infarction + chronic heart failure). During 15 years in the Russian Federation the frequency of administration of beta-blockers increased from 20% in the section of cardiovascular pathology to 30%. The most sensitive to the use of beta-blockers were patients with a history of AMI and chronic heart failure. Prolonged beta-blockers have been used at the population level only in 2007, but the frequency with any cardiovascular pathology does not exceed the 50% threshold, and the achievement of goals (control heart rate) does not exceed 10% of the level at any pathology. This dependence is associated with low-dose beta-blockers. In any case, the dose of beta-blockers did not exceed 50% of recommended that can be a separate cause of cardiovascular mortality at the population level in Russia.

Refractory Heart Failure Caused by Acute Myocardial Infarction of Left Main Coronary Artery

2011 ◽  
Vol 17 (9) ◽  
pp. S165
Author(s):  
Yoshie Haga ◽  
Shirou Ishihara ◽  
Tokushi Koga ◽  
Eiji Nyuta ◽  
Shigeru Kaseda ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Coronary Artery ◽  
Left Main Coronary Artery ◽  
Left Main ◽  
Refractory Heart Failure

scholarly journals A ortic V alve Repl A cemen T versus Conservative Treatment in A symptomatic Seve R e Aortic Stenosis: The AVATAR Trial

Circulation ◽  
2021 ◽  
Author(s):  
Marko Banovic ◽  
Svetozar Putnik ◽  
Martin Penicka ◽  
Gheorghe Doros ◽  
Marek A. Deja ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Conservative Treatment ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Composite Endpoint ◽  
Early Surgery ◽  
Primary Composite Endpoint ◽  
Asymptomatic Patients

Background: Surgical aortic valve replacement (SAVR) represents a class I indication in symptomatic patients with severe aortic stenosis (AS). However, indications for early SAVR in asymptomatic patients with severe AS and normal left ventricular function remain debated. Methods: The Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR) trial is an investigator-initiated international prospective randomized controlled trial that evaluated the safety and efficacy of early SAVR in the treatment of asymptomatic patients with severe AS, according to common criteria (valve area ≤1 cm 2 with aortic jet velocity >4 m/s or a mean trans-aortic gradient ≥40 mm Hg), and with normal LV function. Negative exercise testing was mandatory for inclusion. The primary hypothesis was that early SAVR would reduce the primary composite endpoint of all-cause death, acute myocardial infarction, stroke or unplanned hospitalization for heart failure, as compared to a conservative strategy according to guidelines. The trial was designed as event-driven to reach a minimum of 35 prespecified events. The study was performed in 9 centers in 7 European countries. Results: Between June 2015 and September 2020, 157 patients (mean age 67 years, 57 % men) were randomly allocated to early surgery (n=78) or conservative treatment (n=79). Follow-up was completed in May 2021. Overall median follow-up was 32 months: 28 months in the early surgery group and 35 months in the conservative treatment group. There was a total of 39 events, 13 in early surgery and 26 in conservative treatment group. In the early surgery group, 72 patients (92.3 %) underwent SAVR with operative mortality of 1.4 %. In an intention-to-treat analysis, patients randomized to early surgery had a significantly lower incidence of primary composite endpoint than those in the conservative arm (HR 0.46, 95 % CI 0.23-0.90, p=0.02). There was no statistical difference in secondary endpoints, including all-cause mortality, first heart failure hospitalizations, major bleeding or thromboembolic complications, but trends were consistent with the primary outcome. Conclusions: In asymptomatic patients with severe AS, early surgery reduced a primary composite of all-cause death, acute myocardial infarction, stroke or unplanned hospitalization for heart failure compared with conservative treatment. This randomized trial provides preliminary support for early SAVR once AS becomes severe, regardless of symptoms.

Sign in / Sign up

Export Citation Format

Share Document